David R. Liu - Oct 24, 2022 Form 4 Insider Report for Prime Medicine, Inc. (PRME)

Role: 10%+ Owner
Signature: /s/ Carman Alenson attorney-in-fact
Stock symbol: PRME
Transactions as of: Oct 24, 2022
Transactions value $: $0
Form type: 4
Date filed: 10/26/2022, 08:00 PM
Previous filing: Oct 19, 2022
Next filing: Jul 26, 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PRME	Common Stock	Conversion of derivative security		+322K	+1.54%		21.2M	Oct 24, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PRME	Series A Convertible Preferred Stock	Conversion of derivative security	$0	-1M	-100%	$0.00^*	0	Oct 24, 2022	Common Stock	322K		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Series A Preferred Stock had no expiration date.

Content

The shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Series A Preferred Stock had no expiration date.